Introduction

Pulmonary arterial hypertension (PAH) is a chronic disease with elevated mPAP (mean pulmonary artery pressure), PAH therapies do not reverse the disease yet improve pulmonary hemodynamics and offer symptomatic relief. Two challenges to these therapies are medication tolerance and patient compliance. Healthcare providers, particularly nurses, play a significant role in bridging the gap to improve medication adherence. Historically, in-home nurse visits have offered disease state education, discussed therapy expectations and provided support tools for patients when experiencing adverse events which might lead to therapy discontinuation. During the COVID-19 pandemic, however, many traditional face-to-face nurse visits transitioned to remote or telephonic visits instead.

Objective

To compare adherence and compliance rates to oral and inhaled PAH therapies between patients receiving in-home or face-to-face educational nursing visits and telephonic nurse visits.

Methods

From June 2018 to December 2021, we identified patients who initiated a complex oral PAH therapy (riociguat, selexipag or treprostinil) or inhaled treprostinil, supported by a nursing program, using claims data. We defined complex oral PAH therapies as oral multi-step titratable therapies. We divided patients into two groups based on the study period; we assumed live nurse visits occurred between June 2018 and period; we assumed live nurse visits occurred between June 2018 and December 2020, while virtual visits were made based on the suggested cutoff date of April 1, 2020, which marked the transition to primarily virtual nursing visits. While our study assumed virtual visits for the latter half of the observation period, April 1, 2020, to December 31, 2021, 10 to 40% of nursing education visits for riociguat, selexipag, oral treprostinil and inhaled treprostinil were live visits. One notable difference between the live and virtual study groups was the higher incidence of ADEs in the virtual visit group (17.29% vs. 18.15%; p = 0.48). The FFDR was 0.86% lower among patients in the live visit group than in the virtual visit group (17.29% vs. 18.15%; p = 0.48). The live visit group reported fewer ADEs (151 vs. 622; p=0.0001) than the virtual visit group.

Conclusion

Patients receiving live nursing visits for the indexed oral and inhaled PAH therapies in an educational nursing program demonstrated a similar outcome on overall medication compliance as those patients receiving virtual nursing visits. Assumptions of live vs. virtual nursing visits were made based on the suggested cutoff date of April 1, 2020, which marked the transition to primarily virtual nursing visits. While our study assumed virtual visits for the latter half of the observation period, April 1, 2020, to December 31, 2021, 10 to 40% of nursing education visits for riociguat, selexipag, oral treprostinil and inhaled treprostinil were live visits. One notable difference between the live and virtual study groups was the higher incidence of ADEs in the virtual visit setting. While our study did not compare the direct impact of nursing visits vs. not receiving visits, we had previously observed a higher MPR (86.4% vs. 75%; p<0.01) and improved persistence (72% vs. 60.6%; p<0.05) in patients on oral therapies receiving nursing support (riociguat, selexipag, treprostinil) vs. those patients on oral PAH therapies not supported by nursing (ambrisentan, bosentan and macitentan) demonstrating that a multidisciplinary patient support approach contributed to improved patient outcomes.

We identified 2,290 patients in the live visit group and 2,204 in the virtual visit study group. After a median of 174 person-days observed, patients in the live nursing group reported 0.33 more 30-day fills (7.39 vs. 7.06; p = 0.06) and slightly lower MPR (88.6% vs. 89.75%; p<0.02). The FFDR was 0.86% lower among patients in the live visit group than in the virtual visit group (17.29% vs. 18.15%; p = 0.48). The live visit group reported fewer ADEs (151 vs. 622; p=0.0001) than the virtual visit group.

Point of Contact: Evangelia Sourounis
Email: Evangelia.Sourounis@CVSHealth.com

© 2022 CVS Health and/or one of its affiliates. All rights reserved. This document contains proprietary information and cannot be reproduced, distributed or printed without written permission from CVS Health. Data use and disclosure is subject to applicable law, corporate information policies and client contractual limitations.